Taysha Gene Therapies Announces First Pediatric Patient
Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old ...
Read moreInitiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old ...
Read moreDALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on ...
Read more--Notice of allowance will be the fourth U.S. patent granted under Company’s ThermoStem® program targeting obesity and metabolic disorders, including ...
Read moreFirst dose-escalation results for REGN5668 (MUC16xCD28), a costimulatory bispecific, in combination with Libtayo® (cemiplimab) showed encouraging initial activity in patients ...
Read moreLeading biotechnology company is using AWS artificial intelligence to increase manufacturing throughput to deliver medicines faster for patients globallySEATTLE--(BUSINESS WIRE)--At ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.